Gozellix is a drug owned by Telix Innovations Sa. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jul 28, 2035. Details of Gozellix's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11027031 | Kit for radiolabelling |
Jul, 2035
(9 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Gozellix's patents.
Latest Legal Activities on Gozellix's Patents
Given below is the list of recent legal activities going on the following patents of Gozellix.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 4th Year, Large Entity | 27 Nov, 2024 | US11027031 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 16 Aug, 2023 | US11027031 |
| Change in Power of Attorney (May Include Associate POA) | 08 Nov, 2022 | US11027031 |
| Change in Power of Attorney (May Include Associate POA) | 19 Sep, 2022 | US11027031 |
| Recordation of Patent Grant Mailed | 08 Jun, 2021 | US11027031 |
| Patent Issue Date Used in PTA Calculation | 08 Jun, 2021 | US11027031 |
| Issue Notification Mailed | 19 May, 2021 | US11027031 |
| Dispatch to FDC | 10 May, 2021 | US11027031 |
| Application Is Considered Ready for Issue | 07 May, 2021 | US11027031 |
| Issue Fee Payment Received | 06 May, 2021 | US11027031 |
US patents provide insights into the exclusivity only within the United States, but
Gozellix is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Gozellix's family patents as well as insights into
ongoing legal events
on those patents.
Gozellix's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Gozellix's generic launch date based on the expiry of its last outstanding patent is estimated to be Jul 28, 2035 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Gozellix Generic API suppliers:
Gallium Ga-68 Gozetotide is the generic name for the brand Gozellix. 2 different companies have already filed for the generic of Gozellix, with Ionetix having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Gozellix's generic
Alternative Brands for Gozellix
There are several other brand drugs in the same treatment category and using the same active ingredient (Gallium Ga-68 Gozetotide) as Gozellix. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||
|---|---|---|---|---|
| Telix |
| |||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Gallium Ga-68 Gozetotide. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Novartis |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Gallium Ga-68 Gozetotide, Gozellix's active ingredient. Check the complete list of approved generic manufacturers for Gozellix
About Gozellix
Gozellix is a drug owned by Telix Innovations Sa. Gozellix uses Gallium Ga-68 Gozetotide as an active ingredient. Gozellix was launched by Telix in 2025.
Approval Date:
Gozellix was approved by FDA for market use on 20 March, 2025.
Active Ingredient:
Gozellix uses Gallium Ga-68 Gozetotide as the active ingredient. Check out other Drugs and Companies using Gallium Ga-68 Gozetotide ingredient
Dosage:
Gozellix is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| N/A | POWDER | Prescription | INTRAVENOUS |